O'Byrne K - Search Results

1

Design, construction, and analysis of cell line arrays and tissue microarrays for gene expression analysis.

Gately K, Kerr K, O'Byrne K. Gately K, et al. Methods Mol Biol. 2011;784:139-53. doi: 10.1007/978-1-61779-289-2_10. Methods Mol Biol. 2011. PMID: 21898218

2

Transcriptional regulation of IRS5/DOK4 expression in non-small-cell lung cancer cells.

Gray SG, Al-Sarraf N, Baird AM, Gately K, McGovern E, O'Byrne KJ. Gray SG, et al. Clin Lung Cancer. 2008 Nov;9(6):367-74. doi: 10.3816/CLC.2008.n.053. Clin Lung Cancer. 2008. PMID: 19073520

3

Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing.

Wilson TR, Redmond KM, McLaughlin KM, Crawford N, Gately K, O'Byrne K, Le-Clorrenec C, Holohan C, Fennell DA, Johnston PG, Longley DB. Wilson TR, et al. Cell Death Differ. 2009 Oct;16(10):1352-61. doi: 10.1038/cdd.2009.76. Epub 2009 Jun 19. Cell Death Differ. 2009. PMID: 19543235

4

Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer.

Maher SG, Gillham CM, Duggan SP, Smyth PC, Miller N, Muldoon C, O'Byrne KJ, Sheils OM, Hollywood D, Reynolds JV. Maher SG, et al. Ann Surg. 2009 Nov;250(5):729-37. doi: 10.1097/SLA.0b013e3181bce7e1. Ann Surg. 2009. PMID: 19801928

5

A role for IGF-1R-targeted therapies in small-cell lung cancer?

Gately K, Collins I, Forde L, Al-Alao B, Young V, Gerg M, Feuerhake F, O'Byrne K. Gately K, et al. Clin Lung Cancer. 2011 Jan;12(1):38-42. doi: 10.3816/CLC.2011.n.005. Clin Lung Cancer. 2011. PMID: 21273178

6

Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer.

Cathcart MC, Gately K, Cummins R, Kay E, O'Byrne KJ, Pidgeon GP. Cathcart MC, et al. Mol Cancer. 2011 Mar 9;10:25. doi: 10.1186/1476-4598-10-25. Mol Cancer. 2011. PMID: 21388528 Free PMC article.

7

Prostacyclin synthase expression and epigenetic regulation in nonsmall cell lung cancer.

Cathcart MC, Gray SG, Baird AM, Boyle E, Gately K, Kay E, Cummins R, Pidgeon GP, O'Byrne KJ. Cathcart MC, et al. Cancer. 2011 Nov 15;117(22):5121-32. doi: 10.1002/cncr.26168. Epub 2011 Apr 26. Cancer. 2011. PMID: 21523772 Free article.

8

PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.

Paul I, Savage KI, Blayney JK, Lamers E, Gately K, Kerr K, Sheaff M, Arthur K, Richard DJ, Hamilton PW, James JA, O'Byrne KJ, Harkin DP, Quinn JE, Fennell DA. Paul I, et al. J Pathol. 2011 Aug;224(4):564-74. doi: 10.1002/path.2925. Epub 2011 Jun 27. J Pathol. 2011. PMID: 21706479

9

Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: a verification study.

Gately K, Al-Alao B, T Dhillon, Mauri F, Cuffe S, Seckl M, O'Byrne K. Gately K, et al. Lung Cancer. 2012 Feb;75(2):217-22. doi: 10.1016/j.lungcan.2011.06.012. Epub 2011 Jul 30. Lung Cancer. 2012. PMID: 21802763

10

The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.

Gately K, O'Flaherty J, Cappuzzo F, Pirker R, Kerr K, O'Byrne K. Gately K, et al. J Clin Pathol. 2012 Jan;65(1):1-7. doi: 10.1136/jclinpath-2011-200275. Epub 2011 Oct 29. J Clin Pathol. 2012. PMID: 22039281 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

583 results

Search Page

Filters